Venoplant

Quick links to important sections

Venoplant

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venoplant

Quick Facts

Property Description
Active Ingredient Aescin (from Horse Chestnut Extract)
Form Film-coated tablet (Oral)
Pharmacological Class Venotonic agent / Angioprotector
General Purpose Relieving symptoms of leg heaviness and swelling (edema)
Origin Herbal (Phytomedicine)

What Type of Medicine is Venoplant?

Venoplant is classified as a phytomedicine and a venotonic agent, which is a high-level pharmacological class of medicine designed to act on the tone and function of the veins. The medicine is a single-ingredient product derived from the dry extract of the seeds of the Horse chestnut tree (Aesculus hippocastanum). It is commonly available over-the-counter (OTC) in many regions, serving as a primary option for self-management of venous discomfort.

The active marker compound is the triterpenic glycoside known as aescin. The extract is meticulously standardized to ensure that every film-coated tablet contains a consistent, quantifiable amount of aescin. This standardization is critical for therapeutic reliability, distinguishing it from general, non-quantified herbal supplements.

Venoplant Composition and General Purpose

Venoplant is formulated as a film-coated tablet for oral use, providing a systemic route of delivery, where the medicine is absorbed internally and circulated throughout the body. The composition relies on the standardized Horse chestnut dry extract, ensuring reliable delivery of the active substance, which is intended for general use in adults experiencing discomfort.

Its primary general purpose is to support the integrity of the venous circulation. The action of aescin is associated with the stabilization of capillary walls, reducing the abnormal permeability of these vessels to fluids. By mitigating this excessive fluid leakage, Venoplant provides general symptomatic relief for common discomforts such as persistent feelings of leg heaviness and tension that result from compromised venous return.

What side effects are possible with Venoplant?

Possible Side Effects and Safety Information

The official safety profile for Venoplant (standardized Horse Chestnut Seed Extract/Aescin) is established by regulatory documents, defining the reported adverse reactions, frequency classifications, and necessary constraints on use. This information is derived from well-established use data reported to governmental health authorities.


Officially Documented Adverse Reactions and Frequency

The documented adverse reactions are categorized by the body system affected. The precise frequency is Not known for all listed effects, meaning the rate of occurrence cannot be estimated accurately from available spontaneous reports.

System-Organ Class (SOC) Key Adverse Reactions
Gastrointestinal disorders Stomach discomfort, general gastrointestinal complaints
Nervous system disorders Headache, vertigo (dizziness)
Skin and subcutaneous tissue disorders Itching (pruritus), allergic reactions

Population-Specific Safety Constraints

Safety data necessitates explicit limitations on the use of Venoplant in specific populations and conditions as documented in the regulatory label:

  • Hypersensitivity (Allergy): The medicine is contraindicated (should not be used) in individuals with known hypersensitivity to the active substance, Aescin, or any excipients.
  • Children and Adolescents: Use is not recommended in individuals under 18 years of age due to the absence of sufficient data to establish safety in this population.
  • Pregnancy and Lactation: Use is not recommended during pregnancy and lactation, as safety has not been established for these periods.
  • Pre-existing Conditions: A medical professional must be consulted if the individual has pre-existing cardiac or renal insufficiency.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose of the standardized Horse Chestnut Seed Extract (Aescin) is based solely on official regulatory documents, which provide guidance for a suspected overdose scenario.

Official Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Incidence No cases of overdose have been formally reported with the use of the medicinal product.
Anticipated Manifestations A suspected overdose may result in an increased likelihood of experiencing known undesirable effects (side effects).
Population-Specific Notes No population-specific overdose considerations are documented in official regulatory sections.
Emergency Management Management should include appropriate symptomatic and supportive treatment as warranted by the clinical situation.

Actions Mandated by Regulatory Authorities

In the event of a suspected overdose, official documents require specific actions to be taken:

  • Medical advice should be sought if any symptoms develop following the suspected overdose.
  • The treatment approach should be symptomatic and supportive.
  • No specific antidote for Aescin is mentioned in the official labeling.

Connection to the Overall Overdose Profile

The official overdose profile is defined by the absence of reported cases with the standardized extract, confirming that no specific severe or life-threatening manifestations are documented. Consequently, the regulatory guidance focuses on managing the likely event of increased common adverse effects and mandates that medical advice must be sought if any symptoms appear.

Therapeutic Uses of Venoplant

Main Uses and Benefits of Venoplant

Venoplant is a herbal medicinal product primarily used for the treatment of symptoms associated with chronic venous insufficiency. Its formulation is designed to address the physiological changes in the veins of the lower limbs that lead to discomfort and swelling.

Primary Indications

The main application of Venoplant is the relief of symptoms related to impaired venous circulation. These symptoms typically include:

  • Swelling of the legs: Reduction of edema caused by fluid accumulation in the lower extremities.
  • Sensation of heaviness: Alleviation of the feeling of pressure or weight in the legs, often exacerbated by prolonged standing or sitting.
  • Leg pain and cramps: Management of aching or cramping sensations in the calves and ankles.
  • Itching and tension: Relief from skin irritation and the feeling of tightness associated with venous congestion.

Mechanism of Action and Benefits

The therapeutic benefits of Venoplant are derived from its active components, which work to improve the functional state of the blood vessels. The primary physiological effects include:

  • Capillary Stabilization: The active ingredients help reduce the permeability of capillary walls, which limits the leakage of fluids into the surrounding tissues, thereby addressing the root cause of swelling.
  • Venous Tone Improvement: It aids in increasing the elasticity and tone of the venous walls, facilitating more efficient blood flow back toward the heart.
  • Anti-inflammatory Properties: The product exerts a mild anti-inflammatory effect on the vascular lining, which contributes to the reduction of pain and localized discomfort.

By addressing these factors, Venoplant helps improve the quality of life for individuals experiencing the functional limitations caused by venous disorders.

Regulatory References

  1. European Medicines Agency (EMA) summary for the public

Eligibility and Restrictions for Use

Who Can and Cannot Use Venoplant? — Official Regulatory Information

The eligibility for using Venoplant (standardized Horse Chestnut Extract/Aescin) is strictly defined by official regulatory documentation, primarily limiting use to the adult population and prohibiting use in specific clinical conditions.

Category Official Regulatory Status
Populations Allowed Adults (18 years and older) who do not have any contraindications.
Populations Contraindicated Patients with known hypersensitivity to the active substance (Aescin) or any excipients. Patients with pre-existing Kidney Disease/Renal Impairment or Liver Disease/Hepatic Impairment.
Age Restrictions Use is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established in these groups.
Pregnancy/Lactation Status Use is not recommended during pregnancy and breastfeeding due to the absence of sufficient reliable safety data.
Additional Restrictions The product must be discontinued at least 2 weeks prior to surgery due to regulatory warnings regarding the potential influence on blood clotting.

Connection to the overall eligibility profile:

Official regulatory documents define the eligible user population by establishing non-negotiable prohibitions, classifying conditions like severe liver or kidney dysfunction and hypersensitivity as formal contraindications. Use is also formally not recommended for all pediatric patients and during pregnancy or lactation, restricting usage strictly to the general adult population free of these specific exclusions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for the active ingredient in Venoplant, Aescin (standardized Horse Chestnut Seed Dry Extract), is structured by the formal statements documented in authoritative governmental regulatory sources, such as the European Medicines Agency (EMA) Monograph.

Interaction Type Official Regulatory Statement
Medicinal product categories with documented interactions None reported.
Mechanistic basis of interactions None reported.
Timing-based interaction rules None required.
Interaction-related restrictions None reported.

Official Interaction Statements:

  • The EMA Monograph, which provides the regulatory basis for the well-established medicinal use of this active herbal substance, officially states that no interactions with other medicinal products or other forms of interaction have been reported in the labeling.
  • This documented absence covers the official regulatory assessment of potential risks related to pharmacokinetic interactions, including enzyme-mediated effects, and transporter-mediated changes to exposure.
  • The regulatory documentation similarly contains no formal listing of pharmacodynamic interactions, such as additive or synergistic effects with other medicinal products.
  • As a result of this regulatory status, the official prescribing information includes no mandatory administration spacing, no formal contraindicated combinations based on interaction risk, and no population-specific interaction constraints.

Connection to the overall interaction profile: The medicine’s official interaction profile is characterized by the explicit regulatory declaration of an absence of reported interaction risk in the government labeling. This status establishes the final structure of the official interaction profile, precluding the need for mandatory co-administration prohibitions, exposure modification warnings, or timing separation rules.

Mechanism of Action

Venoplant's core pharmacodynamic activity is attributed to its complex constituent profile, including escin, diosmin, and coumarin, which target the vasculature and associated connective tissue. Escin, a triterpene saponin, acts as an inhibitor of lysosomal enzymes, specifically hyaluronidase and elastase. This enzyme inhibition reduces the degradation of proteoglycans and elastin within the capillary basement membrane, resulting in a reduction of capillary wall permeability. Diosmin, a flavonoid, enhances venous tone by prolonging the vasoconstrictor effect of norepinephrine on the venous wall, directly modulating the systemic venular system. Coumarin inhibits prostaglandin synthesis, leading to decreased local inflammatory signaling. This multi-component mechanism stabilizes the microcirculatory endothelial barrier, restricts macromolecular extravasation into the interstitium, and increases basal venous contractility, resulting in modulated fluid dynamics and reduced interstitial fluid accumulation across the microvascular system.

Dosage and Administration Information

The usage of the standardized Horse Chestnut seed dry extract (Aescin) formulation follows a specific protocol to ensure administration aligns with recognized use. The route for the Venoplant film-coated tablet is oral use, establishing a systemic delivery method for the active substance.

Administration Protocol

Instruction Aspect Information
Active Substance Strength Standardized to 50 mg triterpene glycosides, calculated as aescin equivalent, per unit dose.
Dosing Frequency The standardized dose is administered twice daily, resulting in a typical total daily intake of 100 mg aescin equivalent.
Duration of Use For use in chronic venous conditions, a treatment course typically requires a minimum duration of four weeks before the therapeutic value can be properly evaluated.
Population Restriction The oral formulation is for use in adults and the elderly; its use is not recommended for children or adolescents under 18 years of age.

Procedural Structure

The standard oral protocol involves taking a single 50 mg aescin equivalent dose in the morning and a second dose in the evening. This establishes a procedural structure defined by frequency, adherence to the standardized strength, and compliance with the specified minimum course duration. This structure defines the conditions under which the product is used in practice, limiting its application to the adult patient population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Venoplant

Evidence for use in Chronic Venous Insufficiency (CVI)

Venoplant, containing standardized Horse Chestnut Seed Extract (Aescin), was studied for the common symptoms associated with Chronic Venous Insufficiency (CVI). These outcomes related to physical discomfort include the persistent feeling of leg heaviness, tension, and visible swelling, or edema. The primary way researchers explored the potential effects was through Randomized Controlled Trials (RCTs), where different patient groups receiving the extract were compared against groups receiving an inactive substance (placebo). Multiple systematic reviews and meta-analyses have compiled data from these various short-term trials examining the standardized extract.

Studies monitored both patient-reported outcomes describing perceived discomfort and objective measures like changes in measured leg volume. Findings generally describe patterns observed in the studies where patients receiving the standardized extract reported changes in symptoms compared to the placebo groups over defined time intervals. Research highlights that changes measured during the study period often involved changes in measured leg volume, an objective marker of swelling. In addition, research explored changes in patient-reported symptoms, such as aching pain and leg heaviness.

Types of Studies and Outcomes Measured

Research primarily covers short-term symptom changes and is relevant in evidence describing how symptoms are measured. The research was primarily conducted on adults who were experiencing conditions characterized by fluctuating or episodic manifestations of CVI, mostly in its mild-to-moderate stages. The outcomes reflecting daily functioning or activity level were a key focus. Beyond patient feelings, researchers also examined hard measurements of physical change. This included using a technique called volumetry to measure changes in leg volume (a measure of swelling), which is a physical marker of swelling (edema).

Long-Term Evidence and Follow-up Duration

The majority of high-quality, controlled research is relevant in trials assessing short-term or episodic symptom patterns. Most pivotal RCTs observed responses over defined time intervals lasting from approximately 4 to 16 weeks. This means that while research provides insight into short-term changes, the follow-up durations were limited. Currently, long-term effects are not fully established. There is limited information for long-term outcomes regarding whether any observed changes last reliably over many months or years. Evidence related to whether any observed changes last over extended periods remains an area where certainty remains low and data are still emerging.

Key Studies & References Horse Chestnut - National Center for Complementary and Integrative Health (NCCIH)

Frequently Asked Questions (FAQ)

Common questions about Venoplant (FAQ)


Q: Is Venoplant available over the counter?

Venoplant is classified by official bodies as a phytomedicine intended for self-care. Because of this classification, it is commonly available over-the-counter (OTC) in many regions for the management of venous discomfort.


Q: Is Venoplant a prescription medicine?

The medicine is commonly available for self-management (OTC) in many regions. Official product information indicates that it is not generally listed as a mandatory prescription-only medicine.


Q: Can I stop taking Venoplant if my symptoms improve?

Official guidance suggests that a course of treatment typically requires a minimum of four weeks before the therapeutic effect can be properly evaluated. It is important for users to review the duration of use with a healthcare professional after this initial period.


Q: Is Venoplant meant for short-term or long-term use?

Venoplant is indicated for symptoms related to chronic venous conditions, which implies a potentially long-term context. However, official regulatory documents state that continuing long-term use is associated with the necessity of consulting a medical professional.


Q: Are there any known serious side effects associated with Venoplant?

Regulatory reports list adverse reactions, including allergic reactions or hypersensitivity, which are serious enough to be formal contraindications (reasons not to use the drug). The official documentation lists other reported effects, but does not generally categorize them as commonly 'serious'.


Q: What types of medicine should be discussed with a doctor before taking Venoplant?

Official product information advises consulting a doctor if you have pre-existing cardiac or renal insufficiency. Regulatory documents specify that the use of medicines that slow blood clotting (like anticoagulants) or medicines for diabetes are points for discussion, as caution is advised with these categories.


Q: Are there different strengths or formulations of Venoplant?

The standard formulation defined in the official documentation is a film-coated tablet containing 50 mg of aescin equivalent. However, various other oral or topical preparations containing Horse Chestnut extract may also be available on the market under different names or strengths.


Q: Is Venoplant approved by the FDA or other regulatory bodies?

The product is standardized according to regulatory documentation published by the European Medicines Agency (EMA). Its official regulatory status with other bodies, such as the FDA in the United States, may vary, as the substance is often sold as an herbal supplement in non-European markets.


Q: What does it mean if Venoplant is 'contraindicated' for a certain group?

A contraindication is a clear regulatory term meaning the medicine must not be used by individuals with a specific condition. This is because the risk of harm is clearly established for that group, such as those with severe kidney or liver impairment or a known hypersensitivity.


Q: Is a medical check-up needed before starting Venoplant?

Official regulatory documents define circumstances, such as the presence of pre-existing conditions like cardiac or renal insufficiency, that require prior discussion with a medical professional. Consultation is additionally noted for symptoms that include sudden swelling, signs of skin infection, or other severe discomfort.


Q: Does Venoplant treat the root cause or just the symptoms?

Official labeling states that the medicine is indicated for relieving symptoms of chronic venous insufficiency, such as leg heaviness and swelling. Its pharmacological action works by stabilizing microcirculatory vessel walls to mitigate fluid leakage.


Q: How long does it typically take to notice the effects of Venoplant?

Clinical studies examining the effects of the extract assess changes over defined periods of time. Research reports indicate that measurable changes in leg swelling and pain are often established over treatment intervals lasting approximately four to 16 weeks.


Q: Do I have to take Venoplant forever once I start?

No, the recommended treatment course requires a minimum of four weeks for symptom evaluation. The potential for continued long-term use is associated with the necessity of consulting a medical professional.


Q: What happens if I forget to take a dose of Venoplant?

General pharmaceutical guidance from authoritative sources advises against taking a double dose to compensate for a missed dose. The guidance suggests continuing the course by taking the next scheduled dose as usual.


Q: Can people with diabetes use Venoplant?

Official product information notes that blood sugar level monitoring is a necessary consideration for individuals with diabetes while using Venoplant. Caution is advised because the active substance may potentially influence blood sugar.


Q: What are the signs that Venoplant is not working for someone?

According to official regulatory documents, signs that the medicine may not be sufficient include a worsening of existing symptoms or the appearance of signs of skin infection. If these occur, consultation with a doctor is described in the regulatory documents.


Q: Can I crush or chew Venoplant tablets?

The product is manufactured as a film-coated tablet for oral use. The general guidance for film-coated products reflects that they are intended to be swallowed whole and not be crushed or chewed, unless the official instructions explicitly state otherwise.


Q: Can Venoplant be used in combination with compression stockings?

Regulatory and clinical summaries acknowledge that standardized Horse Chestnut extract is often viewed as an alternative to compression stockings for managing chronic venous insufficiency symptoms. This suggests that it may potentially be used in a combined management approach.


How should Venoplant be stored and disposed of?

The required storage and disposal of Venoplant are defined by regulatory labeling to maintain product stability and safety.

Storage & Disposal Scope

Classification Requirement
Labeled Storage Temperature Not explicitly published in general governmental monographs.
Protection Requirements Stability studies support the need to protect the product's integrity (e.g., from moisture) by keeping it in the original packaging.
Child-Protection Must be stored out of the sight and reach of children, as mandated for all pharmaceutical products.
Disposal Instructions Unused or expired tablets must be disposed of according to local regulatory requirements (e.g., drug take-back programs).

The expiration date is validated only when the tablets have been continuously stored in the original, unopened packaging under the conditions specified in the approved regulatory document. Disposal must follow the official pharmaceutical waste protocols established by the local governing authority to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venoplant found in:

A-Z Index: